- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- May 2024
- 134 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- January 2022
- 110 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- June 2019
- 18 Pages
Global
€9478EUR$10,000USD£7,918GBP
- Report
- February 2024
- 83 Pages
Global
From €3500EUR$3,956USD£3,026GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- June 2019
- 15 Pages
Japan
€9478EUR$10,000USD£7,918GBP
Tenofovir is an antiretroviral drug used to treat HIV/AIDS. It is a nucleotide reverse transcriptase inhibitor (NRTI) that works by blocking the action of the reverse transcriptase enzyme, which is responsible for the replication of HIV. Tenofovir is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of infection. Tenofovir is available in both oral and injectable forms.
Tenofovir is a widely used antiretroviral drug for the treatment of HIV/AIDS. It is generally well tolerated and has few side effects. It is also effective in reducing the risk of HIV transmission. Tenofovir is available in generic form, which makes it more affordable for people living with HIV/AIDS.
Some companies in the Tenofovir market include Gilead Sciences, ViiV Healthcare, Mylan, and Cipla. Show Less Read more
